Introduction
Atherosclerosis and its complications in the cardiovascular system are the most common cause of death and disability worldwide. The World Health Organization reported that 30% of all deaths were attributed to cardiovascular diseases in 2010, and it is estimated that by 2030 at least 23.3 million people will die because of cardiovascular disease every year [1] .
Atherosclerosis causes many pathologies by affecting the vascular system in different parts of the body. The ischemia that occurs as a result triggers an inflammatory response in many organs [2] . The most common etiological cause of coronary artery disease (CAD), carotid artery disease and peripheral artery disease is atherosclerosis [3] .
Stroke is one of the most important causes of death and disability in the world [4] . Approximately 87% of the strokes are ischemic, 10% due to intracerebral hemorrhage, and 3% due to subarachnoid hemorrhage [5] . Seventy-five percent of ischemic strokes result from carotid artery stenosis [6] .
The incidence of carotid artery disease increases with age and cardiovascular risk factors [7] . Significant carotid artery stenosis is closely related to the development of stroke and other cerebrovascular events. Other etiologic factors of carotid artery stenosis are fibromuscular dysplasia, kink formation due to elongation, traumatic occlusion, intimal dissection and chronic inflammatory angiopathy [8] . Medical treatment, endovascular intervention or surgical treatment is preferred in the treatment of carotid artery stenosis. In the current era, the gold standard treatment of atherosclerotic carotid artery stenosis is surgical therapy [9, 10] .
Cytomegalovirus (CMV) is a member of the Herpesviridae family, which includes large, enveloped viruses containing double-stranded DNA. Like other forms of the herpes family, it has the ability to remain latent in the tissue following acute infection and reactivate when immunity is suppressed.
It is thought that CMV triggers the coagulation cascade, and induces atherosclerosis through the lipid metabolism modification following arterial wall injury and hypercholesterolemia.
In our study, we aimed to show the effect of CMV on triggering the chronic inflammatory process in the pathophysiology of atherosclerosis, and its presence and impact in the plaques leading to carotid artery stenosis.
Material and methods
We included 36 patients who underwent a carotid endarterectomy (CEA) operation at the Department of Cardiovascular Surgery, Istanbul University Istanbul Medical Faculty between April 2017 and April 2018 and regularly visited the outpatient clinic after the operation. The same surgeon (M.U.) operated on 35 patients and the remaining one was performed by a different surgeon.
Among 36 patients included in the study, 58.3% (n = 21) were male and 41.7% (n = 15) were female. 66.7% were 65 years old or over with a mean age of 67.5 ±9.6 years and a median age of 68 years (minimum: 42, maximum: 85).
Patients with additional immunosuppressive conditions (malignancy, chronic autoimmune disease, AIDS, etc.) were not included in the study. Unilateral atheromatous plaque was preferred for patients undergoing bilateral carotid endarterectomy and all risk factors (DM, HT, hyperlipidemia, etc.) were evaluated together for all patients.
Age, sex, height and weight were initially recorded for each voluntary patient. Patients' body mass index (BMI) values were calculated. The diagnosis of hypertension, diabetes mellitus and chronic renal failure (CRF), presence of neurological symptoms before the operation, bilateral CEA operation necessity, history of smoking and alcohol use, previous cardiovascular interventions and family history were questioned. Preoperative carotid artery stenosis rates were provided from preoperative radiological imaging results (such as carotid duplex ultrasonography, computed tomography angiography, magnetic resonance angiography, and subtraction angiography).
All patients underwent conventional carotid endarterectomy. Operations were performed with continuous neurological evaluation during carotid arterial clamping under cervical regional block. A Dacron patch was used in all patients.
Samples taken from the patients after a conventional carotid endarterectomy procedure were placed into sterile petri dishes and pre-mechanically disintegrated with a scalpel. Subsequently, 400 μl of tissue lysis solution and 40 μl of proteinase K were added to 2 ml sterile Eppendorf tubes to perform 56°C overnight tissue disruption (Buffer ATL (Cat no: 939011), Proteinase K (Cat no: 19133; Qiagen)). Quantitation of CMV samples in the green channel was performed by PCR analysis. In the yellow channel, the internal control used during the isolation phase was assessed, which allows us to check the isolation and PCR stage correctly.
Surgical technique
Operations were performed under regional block and local anesthesia. The common carotid artery and the internal and external carotid arteries were prepared by an incision parallel to the sternocleidomastoid muscle. Following systemic heparinization (5000 IU), the arteries were clamped. The patient's consciousness and neurological status was evaluated prior to arteriotomy with oral stimulation and foot and hand move-ments on the contralateral half of the body in response to commands. Neurological deterioration was not detected in any patients. If neurological disorder was detected, endarterectomy would be performed with a shunt. Endarterectomy was performed after a standard longitudinal incision in all patients and internal carotid arteries were reconstructed using patch material. In patients with bilateral carotid artery stenosis, primarily, the symptomatic side was treated; otherwise the more stenotic side was operated on. The extracted plaque material was sent to the microbiology laboratory under appropriate conditions for microbiological examination.
CMV-DNA analysis
Clinical specimens obtained from the patients after conventional carotid endarterectomy were first subjected to physical disintegration with the help of a scalpel in sterile petri dishes. After the procedure, the shredded clinical specimens were placed in 20 mg sterile Eppendorf tubes with 400 μl of tissue lysis solution (Qiagen, Cat no: 939011), and 40 μl of proteinase K (Qiagen, Cat no: 19133) was added, in accordance with the kit procedure, to perform overnight incubation at 56°C. Then, 600 μl of AVE solution was added into the Eppendorf tubes containing the clinical specimens, and CMV DNA extraction was performed. Extraction of the samples was performed using the DSP Virus/ Pathogen midi kit (Qiagen, Cat no. 937055) on the Qiasymphony SP/AS platform. PCR was performed using the Artur CMV QS-RGQ kit (24) (Cat no: 4503363) on a Rotorgene Q instrument. Assessment of the results was based on the Rotorgene Q device in the green channel showing the presence of CMV DNA in clinical specimens and in the yellow channel displaying the internal control for any inhibition in the study.
Statistical analysis
All analyses were performed with the IBM SPSS Statistics software package (version 21.0, IBM, Armonk, NY, USA) at the 95% confidence level and p < 0.05 significance level. Quantitative variables were reported as the mean and standard deviation (SD); qualitative variables were described as numbers and percentages. Quantitative variables were analyzed by Friedman analysis for dependent groups. Subgroup analysis was performed by Wilcoxon analysis and interpreted by Bonferroni correction. The independent groups were compared with c 2 analysis.
Results
Thirty-six patients participated in the study. 58.3% (n = 21) of the patients were male and 41.7% (n = 15) were female. 66.7% of the patients were aged 65 years or over, with a mean age of 67.5 ±9.6 years and a median age of 68 years (minimum: 42, maximum: 85). In terms of co-morbidity, 66.7% of the patients had DM, 61.1% had HT and 55.6% had hyperlipidemia. Twenty-four patients were active smokers and 8 patients were ex-smokers (Table I) .
The relationships between the presence of CMV (DNA) and sex, age and comorbidities in the samples taken from the patients' plaques were examined: CMV (DNA) positivity (45.8%) was sig- nificantly higher in DM patients than in non-DM patients (8.3%) (p = 0.024). Similarly, CMV (DNA) positivity (40%) was significantly higher in HT patients than in non-HT patients (25%) (p = 0.008). When CMV (DNA) positivity was examined according to the presence of bilateral carotid artery stenosis, the rate of CMV (DNA) positivity was found to be significantly higher in patients with bilateral carotid artery stenosis (63.16%) compared to patients without bilateral carotid artery stenosis (p < 0.001) (Table II, III, Figures 1-3) .
When plaque quantities were compared according to the gender, CMV (DNA), bilateral carotid artery stenosis and co-morbidity, the median value of sample quantities in patients with bilateral carotid artery stenosis (1280.00) was significantly higher than that in the patients without bilateral carotid artery stenosis. Similarly, the median value (1340.00) of sample quantities from patients with CMV (DNA) was significantly higher than that of the CMV (DNA) negative patients (Table IV) .
Discussion
The potential pathological mechanism of atherosclerosis is still unclear, and it is known that certain risk factors such as hypertension, hyper- cholesterolemia, smoking, hyperlipidemia, diabetes, and genetic predispositions are important factors. In addition, the number of studies suggesting that infectious agents such as C. pneumoniae, H. pylori and some herpesviruses may be effective in the development of atherosclerotic pathology by triggering an inflammatory response in vascular tissues has increased in recent years [11] [12] [13] . Human CMV (HCMV), one of the most studied viruses associated with atherosclerosis, is an important human pathogen that causes disease especially in immunosuppressed hosts and remains persistently in the host after primary infection as a highly complex virus. There are many studies suggesting that CMV may cause a latent infection in the vascular wall, resulting in an inflammatory process with reactive damage, leading to the onset of atherosclerosis. However, there are studies that find contradictory results with this opinion. It is not clear yet whether this virus triggers atherosclerosis primarily, or secondarily through a pre-existing lesion due to its affinity [12, 13] .
In the literature, there are a limited number of publications about the relationship between CMV seropositivity and gender. According to the study performed by Mayr et al. [14] in 2000, CMV seropositivity was found significantly higher in women than men (p < 0.001) in patients with carotid and femoral artery atherosclerosis. In contrarst, Zhu et al. [15] reported that CMV seropositivity was significantly higher in males than females in patients with atherosclerosis based on coronary artery disease (p < 0.001). According to this, the distribution of CMV seropositivity by gender varies in a small number of studies.
In our study, 33.3% CMV (DNA) positivity was detected in the atherosclerotic tissue specimens belonging to the patient group. In the literature, there are some studies that showed different results from ours. Watt et al. [12] studied 16 atherosclerotic carotid artery tissues, and Müller et al. [16] studied 53 carotid artery plaques, and they did not detect CMV (DNA) in any tissue sample. Likewise, in 2005, Ibrahim et al. [17] found 10% CMV (DNA) positivity in atherosclerotic tissue samples taken from 46 coronary and 2 carotid arteries, without detecting CMV (DNA) in non-atherosclerotic tissue specimens, but they reported that there was no statistical correlation among the findings. In our country, in 2006, Kılıç et al. [18] found CMV (DNA) positivity in 37.9% of the atherosclerotic tissue specimens taken from coronary, carotid and abdominal arteries and 32.7% of the non-atherosclerotic tissue specimens and also reported that there was no significant difference between them.
Our study is based on a single center and a limited number of patients' experiences. Although we found high CMV (DNA) positivity in specimens, we could not identify whether CMV triggers the pathway that leads to atherosclerosis. These may be considered as limitations of our study.
Although CMV (DNA) has not been identified in some international studies, we believe that the presence of CMV (DNA) positivity in 12 (33.3%) cases in our study and the high rates of the presence of CMV (DNA) in atherosclerotic tissue samples in many international studies may reinforce the claims that it may play a role in the etiopathogenesis of atherosclerosis as a primary agent, rather than being secondary due to its affinity to the tissue.
In conclusion, our results show a significant relationship between CMV and atherosclerosis, but further studies are needed. Especially, when CMV (DNA) positivity is examined according to the presence of bilateral carotid artery stenosis in our study, CMV (DNA) positivity was found significantly higher in patients with bilateral carotid artery stenosis than in those without (63.16%). High positive rates suggest that CMV, an important component of the chronic inflammatory process, is a pathogen that should be considered seriously on the basis of atherosclerosis.
